• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ABVX

    Abivax SA

    Subscribe to $ABVX
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2023

    Exchange: NASDAQ

    Recent Analyst Ratings for Abivax SA

    DatePrice TargetRatingAnalyst
    7/23/2025$71.00Equal-Weight → Overweight
    Morgan Stanley
    3/20/2025$12.00Equal-Weight
    Morgan Stanley
    12/4/2024$33.00Mkt Outperform
    JMP Securities
    7/29/2024$48.00Buy
    Laidlaw
    5/20/2024$43.00Buy
    BTIG Research
    4/29/2024$42.00Overweight
    Piper Sandler
    4/29/2024$50.00Buy
    Guggenheim
    11/14/2023$15.00Equal-Weight
    Morgan Stanley
    11/14/2023$20.00Outperform
    Leerink Partners
    See more ratings

    Abivax SA Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

      Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces that the underwriters of its offering of 10,156,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States (the "Offer

      7/25/25 2:00:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

      Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company, in the United States at an offering price of $64.00 per

      7/24/25 8:40:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax announces trading resumption of its ordinary shares on Euronext Paris

      Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. CEST. Trading of the ordinary shares of the Company was halted at the request of the Company on July 24, 2025 from 9:00 a.m. CEST in the context of the previously announced public offering by the

      7/24/25 8:40:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

      Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris ("Euronext Paris") will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced public offering by

      7/24/25 1:30:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Launch of Public Offering

      Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its American Depositary Shares ("ADSs"), each representing one ordinary share, €0.01 nominal value per share (each an "Ordinary Share"), of the Company in the United States (the "Of

      7/23/25 4:15:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

      Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis   50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a placebo-adjusted remission rate of 13.4% (p=0.0001) in ABTECT-2.50 mg once-daily dose of obefazimod met all key secondary endpoints demonstrating highly statistically significant and clinica

      7/22/25 4:05:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Results of its June 6, 2025 Annual General Meeting

      Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

      6/11/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Presents First Quarter 2025 Financial Results

      Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business and operational goals in press releases published: On January 9, 2025 in a press release titled "Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment"On January 23, 2025 in a press rele

      6/2/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

      Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026.Blinded baseline characteristics align with pre-specified target population and are consistent with Phase 2b UC trial participant characteristics Cash run

      4/29/25 4:05:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

      Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General

      4/22/25 4:05:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Abivax SA SEC Filings

    See more

    Abivax SA Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 424B5 filed by Abivax SA

      424B5 - Abivax S.A. (0001956827) (Filer)

      7/24/25 4:45:36 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      7/24/25 4:12:13 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form FWP filed by Abivax SA

      FWP - Abivax S.A. (0001956827) (Subject)

      7/24/25 8:52:56 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form FWP filed by Abivax SA

      FWP - Abivax S.A. (0001956827) (Subject)

      7/23/25 5:26:38 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Abivax SA

      424B5 - Abivax S.A. (0001956827) (Filer)

      7/23/25 5:08:09 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form F-3ASR filed by Abivax SA

      F-3ASR - Abivax S.A. (0001956827) (Filer)

      7/23/25 4:02:08 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      7/22/25 5:17:03 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      6/11/25 4:01:43 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      6/2/25 4:04:23 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Abivax SA

      6-K - Abivax S.A. (0001956827) (Filer)

      4/29/25 4:04:55 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax SA upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Abivax SA from Equal-Weight to Overweight and set a new price target of $71.00

      7/23/25 8:43:44 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Abivax SA with a new price target

      Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $12.00

      3/20/25 7:58:37 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Abivax SA with a new price target

      JMP Securities initiated coverage of Abivax SA with a rating of Mkt Outperform and set a new price target of $33.00

      12/4/24 7:19:08 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw initiated coverage on Abivax SA with a new price target

      Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00

      7/29/24 7:18:58 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Abivax SA with a new price target

      BTIG Research initiated coverage of Abivax SA with a rating of Buy and set a new price target of $43.00

      5/20/24 7:14:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Abivax SA with a new price target

      Piper Sandler initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $42.00

      4/29/24 7:14:38 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Abivax SA with a new price target

      Guggenheim initiated coverage of Abivax SA with a rating of Buy and set a new price target of $50.00

      4/29/24 7:14:07 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Abivax SA with a new price target

      Morgan Stanley initiated coverage of Abivax SA with a rating of Equal-Weight and set a new price target of $15.00

      11/14/23 7:31:48 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Abivax SA with a new price target

      Leerink Partners initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $20.00

      11/14/23 7:31:22 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Abivax SA Leadership Updates

    Live Leadership Updates

    See more
    • Abivax Announces Results of its June 6, 2025 Annual General Meeting

      Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

      6/11/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

      Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

      4/22/25 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

      Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

      11/13/24 4:01:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax Provides Operational and Key Program Update

      Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-

      7/15/24 4:00:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

      PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the "General Meeting"), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation poli

      6/4/24 4:10:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor

      Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova's portfolio companies on corporate and financial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312683597/en/Troy Ignelzi, Executive Advisor, Sofinnova Investments (Photo: Business Wire) Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors. He is currently Chief Financial Officer at Rapport Therapeutics, a clinical-stage biotechnology company leveraging

      3/12/24 8:00:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abivax appoints Ana Sharma as Vice President, Global Head of Quality

      Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ms. Sharma brings over 20 years of experience in the biopharmaceutical industry and has a strong track record in quality and GxP compliance. She has helped bring over 30 drugs to market across multiple therapeutic areas, including

      2/7/24 2:30:00 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Abivax SA Financials

    Live finance-specific insights

    See more
    • Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

      Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis   50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a placebo-adjusted remission rate of 13.4% (p=0.0001) in ABTECT-2.50 mg once-daily dose of obefazimod met all key secondary endpoints demonstrating highly statistically significant and clinica

      7/22/25 4:05:00 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Abivax SA Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Abivax SA

      SC 13G/A - Abivax S.A. (0001956827) (Subject)

      11/14/24 9:09:55 AM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Abivax SA

      SC 13G - Abivax S.A. (0001956827) (Subject)

      4/19/24 7:09:50 PM ET
      $ABVX
      Biotechnology: Pharmaceutical Preparations
      Health Care